




**GORE® VIABAHN® VBX**  
Balloon Expandable Endoprosthesis

FLEXIBLE STRENGTH.  
PROVEN SUCCESS.



*Together, improving life*

## Proven procedural and clinical success

---


The Gore VBX FLEX Clinical Study is a prospective, multicenter, single-arm study of 134 patients with complex aortoiliac occlusive disease (32.1% TASC II C and D, 42.5% kissing stent).

In the study, 234 devices were delivered; 50% bilateral treatment, 18% contralateral deliveries and predilatation was not required.

---

# 100%

restoration of lumen diameter<sup>1</sup>



Before

After

---

≤ 30% residual stenosis due to high radial strength, even in highly calcified and non-compliant lesions

---

# 100%

delivery to target lesion with no device dislodgement<sup>1</sup>

# 100%

stent retention<sup>1</sup>

# 100%

deployment at the target site<sup>1</sup>

# Proven patency and patient benefit

## One-year outcomes

94.5%  
primary patency<sup>2</sup>

96.1% primary patency in TASC C and D lesions at one year<sup>2</sup>

---

99.5% secondary patency<sup>2</sup>

## Three-year outcomes

91.2% freedom from target lesion revascularization (fTLR)<sup>2</sup>

---

+.17 improvement in mean resting ABI ( $P < .001$ , .93 mean ABI)<sup>\*,2</sup>

---

92% of patients improved  $\geq 1$  Rutherford category versus baseline<sup>2</sup>

\* ( $P < .001$ ) Statistically significant change from pre-procedure.

# Clinically proven results<sup>3</sup>

VBX Stent Graft durability through five years assessed in a physician-initiated study that enrolled 59 patients from three participating centers representative of the VBX FLEX Study cohort.

Physician-initiated **five-year** follow-up of patients from three centers participating in the VBX FLEX Study

## Five-year outcomes

89.5%


primary patency per lesion

96.1%

primary assisted patency per lesion

89.1%

fTLR per subject



Kaplan Meier graph of primary patency with number of lesions at risk

# Additional patient benefits versus baseline<sup>3</sup>

Follow-up of patients treated with the **VBX Stent Graft**

## Five-year outcomes

**+.15** improvement in mean resting  
ankle-brachial index (ABI)  
(from .76 to .95) [ $P < .001$ ]\*

---

**3x** improvement in median  
WIQ measures


---

**89%** of patients improved  $\geq 1$  Rutherford  
category versus baseline

\* ( $P < .001$ ) Statistically significant change from pre-procedure.


# Physician initiated five year follow-up elevates BX stent graft long-term data

Physician initiated VBX Stent Graft follow-up<sup>3</sup>



VBX Stent Graft  
primary patency  
**89.5%**

COBEST Clinical Study<sup>4</sup>



CS  
primary patency  
**74.7%**

Note: Key differences in study design and patient population hinder a direct comparison of results from COBEST and physician-initiated study.

# Advanced technology and unique design

The only BX stent graft with stainless steel independent rings<sup>5-9</sup>:

- Enhances flexibility and conformability
- Minimizes foreshortening
- Provides high radial strength




The only BX stent graft with a semi-compliant covered balloon<sup>5-9</sup>:

- Enables diameter customization
- Improves device retention on the catheter while tracking in tortuous anatomy and tight angles




Broadest offering of diameters and lengths<sup>5-9</sup>:

- The longest BX stent graft
- The biggest max post-dilated stent diameter BX stent graft\*



Proven leader in stent graft technology:

- Twenty years of peripheral stent graft clinical experience
- Leverages the stent graft technology of the GORE® VIABAHN® Endoprosthesis
- Featuring Gore's CBAS® Heparin Surface, the proven heparin bonding technology for lasting thromboresistance<sup>10</sup>



\* Expansion beyond 13 mm is outside of the indication – see *Instructions For Use*.

## References

1. Bismuth J, Gray BH, Holden A, Metzger C, Panneton J; VBX FLEX Study Investigators. Pivotal study of a next-generation balloon-expandable stent-graft for treatment of iliac occlusive disease. *Journal of Endovascular Therapy* 2017;24(5):629-637. <http://journals.sagepub.com/doi/full/10.1177/1526602817720463>
2. Panneton JM, Bismuth J, Gray BH, Holden A. Three-year follow-up of patients with iliac occlusive disease treated with the Viabahn Balloon-Expandable Endoprosthesis. *Journal of Endovascular Therapy* 2020;27(5):728-736. <https://journals.sagepub.com/doi/10.1177/1526602820920569>
3. Holden A, Takele E, Hill A, *et al.* Long-Term Follow-up of Subjects With Iliac Occlusive Disease Treated With the Viabahn VBX Balloon-Expandable Endoprosthesis. *Journal of Endovascular Therapy*. 2023;0(0). doi:10.1177/15266028231165723
4. Mwiipatayi BP, Sharma S, Daneshmand A, *et al*; COBEST co-investigators. Durability of the balloon-expandable covered versus bare-metal stents in the Covered versus Balloon Expandable Stent Trial (COBEST) for the treatment of aortoiliac occlusive disease. *Journal of Vascular Surgery* 2016;64(1):83-94.e1.
5. GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis [Instructions for Use]. Flagstaff, AZ: W. L. Gore & Associates, Inc; 2021. MD172259
6. BeGraft Peripheral Plus Stent Graft System [Instructions for Use]. Hechingen, Germany: Bentley InnoMed GmbH. BeGraft Peripheral Stent Graft System [Instructions for Use]. Hechingen, Germany: Bentley InnoMed GmbH.
7. BD® LIFESTREAM® Balloon Expandable Vascular Covered Stent [Instructions for Use]. Tempe, AZ: Bard Peripheral Vascular, Inc; 2016. PK1345700 Rev. 4 07/16.
8. Advanta V12 balloon expandable Covered Stent [Instructions for Use]. Merrimack, NH; Atrium Medical Corporation.
9. iCover Peripheral balloon expandable PTFE covered stent system [Instructions for Use]. Barcelona, Spain. iVascular S.L.U.
10. CBAS Heparin Surface. W. L. Gore & Associates website. Accessed February 4, 2021. <https://www.goremedical.com/cbas/references>



Refer to *Instructions for Use* at [eifu.goremedical.com](http://eifu.goremedical.com) for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. <sup>Rx Only</sup>

Products listed may not be available in all markets.

CBAS is a trademark of Carmeda AB, a wholly owned subsidiary of W. L. Gore & Associates, Inc.  
GORE, *Together, improving life*, VBX, VBX FLEX, VIABAHN and designs are trademarks of W. L. Gore & Associates.  
© 2023 W. L. Gore & Associates GmbH 231018556-EN MAY 2023

W. L. Gore & Associates, Inc.  
[goremedical.com](http://goremedical.com)

Asia Pacific +65 6733 2882 Australia/New Zealand 1800 680 424 Europe 00800 6334 4673  
United States Flagstaff, AZ 86004 800 437 8181 928 779 2771

